Alterations in p16 and p53 genes and chromosomal findings in patients with lung cancer: Fluorescence in situ hybridization and cytogenetic studies

Cancer Epidemiology

Volumn 34, Issue 4, 2010, Pages 472-477

  Demirhan, Osman ^a   Taştemir, Deniz ^b   Hastürk, Serap ^a   Kuleci, Sedat ^a   Hanta, Ismail ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Aneuploidy; Chromosomal aberrations; Fragile sites; Interphase FISH; Lung cancer; P16 and p53 genes

Indexed keywords

PROTEIN P16; PROTEIN P53; P16 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER RISK; CHROMOSOME 1; CHROMOSOME 18; CHROMOSOME 19; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME 3; CHROMOSOME 9; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TURKEY (REPUBLIC); X CHROMOSOME; Y CHROMOSOME; GENETICS; HUMAN CHROMOSOME; KARYOTYPING; LUNG TUMOR; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CANCER;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SMALL CELL LUNG CARCINOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955091583     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.03.018     Document Type: Article

References (41)

1. Peto R., Lopez A.D., Boreham J., Thun M., Health C. Mortality from smoking in developed countries 1994, Oxford University Press, Oxford, p. 1950-2000.
2. World-Health Organization Tobacco or health: a global status report 1997, World Health Organization, Geneva.
3. Fry W.A., Menck H.R., Winchester D.P. The national cancer data base report on lung cancer. Cancer 1996, 77:1947-1955.
4. Hirsch F.R., Franklin W.A., Gazdar A.F., Bunn P.A. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001, 7:5-22.
5. Zöchbauer-Müller S., Gazdar A.F., Minna J.D. Molecular pathogenesis of lung cancer. Ann Rev Physiol 2002, 64:681-708.
6. Feder M., Siegfried J.M., Balshem A., Litwin S., Keller S.M., Liu Z., et al. Clinical relevance of chromosome abnormalities in non-small cell lung cancer. Cancer Genet Cytogenet 1998, 102:25-31.
7. Karaüzüm S.B., Lüleci G., Özbilim G., Erdoĝan A., Kuzucu A., Demircan A. Cytogenetic findings in thirty lung carcinoma patients. Cancer Genet Cytogenet 1998, 100:114-123.
8. Wong M.P., Fung L.-F., Wang E., Chow W.-S., Chiu S.-W., Lam W.-K., et al. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 2003, 97(5):1263-1270.
9. Schenk T., Ackermann J., Brunner C., Schenk P., Zojer N., Roka S., et al. Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Chest 1997, 11(6):1691-1696.
10. Matsumura K., Kallioniemi O., Kallioniemi A., Chen L., Smith H.S., Pinkel D., et al. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res 1992, 52:3474-3477.
11. Miller C.W., Simon K., Aslo A., Kok K., Yokota J., Buys C.H., et al. p53 mutations in human lung tumors. Cancer Res 1992, 52(7):1695-1698.
12. Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I., et al. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 1994, 54(6):1551-1555.
13. Wang J., Chen C. p16 gene deletions and point mutations in patients with agnogenic myeloid metaplasia (AMM). Leuk Res 1999, 23:631-635.
14. Huang Q., Tao Y., Yandell D.W. Mutations of several tumor suppressor genes in primary retinoblastoma. Zhonghua Zhong Liu Za Zhi 1999, 21(1):10-12.
15. Fundia A.F., Larripa I.B. Coincidence in fragile site expression with fluorodeoxyuridine and bromodeoxyuridine. Cancer Genet Cytogenet 1989, 41:41-48.
16. Mitelman F. ISCN: an international system for human cytogenetics nomenclature 1995, Basel, Skarger.
17. McAlpine P.J., Shows T.B., Boucheli C., Huebner M., Anderson W.A. The 1991 catalog of mapped genes and report of the nomenclature committee, Human Gene Mapping 11. Cytogenet Cell Genet 1991, 58:5-102.
18. Groeger A.M., Caputi M., Esposito V., De Luca A., Bagella L., Pacilio C., et al. Independent prognostic role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 1999, 118:529-535.
19. Dessy E., Rossi E., Berenzi A., Tironi A., Benetti A., Grigolato P. Chromosome 9 instability and alterations of p16 gene in squamous cell carcinoma of the lung and in adjacent normal bronchi: FISH and immunohistochemical study. Histopathology 2008, 52:475-482.
20. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995, 11:210-212.
21. Cairns P., Mao L., Merlo A., Lee D.J., Schwab D., Eby Y., et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994, 265:415-417.
22. Merlo A., Herman J.G., Mao L., LeeDJ, Gabrielson E., Burger P.C., et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995, 1(7):686-692.
23. Awaya H., Takeshima Y., Amatya V.J., Furonaka O., Tagawa K., Kohno N., et al. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung. Pathol Int 2004, 54:486-489.
24. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19(6):607-614.
25. Shin D.M., Lee J.S., Lippman S.M., Lee J.J., Tu Z.N., Choi G., et al. p53 expressions: predicting recurrence and second primary tumours in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996, 88:519-529.
26. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997, 25:151-157.
27. Feder M., Siegfried J.M., Balshem A., Litwin S., Keller S.M., Liu Z., et al. Clinical relevance of chromosome abnormalities in non- small cell lung cancer. Cancer Genet Cytogenet 1998, 102:25-31.
28. Veiga L.C.S., Bergamo NA, Kowalski LP, Rogatto S.R. Classical and molecular cytogenetic analysis in head and neck squamous cell carcinomas. Genet Mol Biol 2003, 26(2):121-128.
29. Matturri L., Lavezzi A.M. Recurrent chromosome alterations in non-small cell lung cancer. Eur J Histochem 1994, 38(1):53-58.
30. Huang Q., Yu G.P., McCormick S.A., Mo J., Datta B., Mahimkar M., et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer 2002, 34:224-233.
31. Amiel A., Sardos-Albertini F., Fejgin M.D. Interchromosomal effect leading to an increase aneuploidy in sperm nuclei in a man heterozygous for pericentric inversion (inv 9) and C-heterochromatin. J Med Genet 2001, 46:245-250.
32. Prabhavathi P.A., Fatima S.K., Rao M.S., Reddy P.P. Analysis of chromosomal aberration frequencies in the peripheral blood lymphocytes of smokers exposed to uranyl compounds. Mutat Res 2000, 466:37-41.
33. Zhang W., Wang C., Chen D., Minamihisamatsu M., Morishima H., Yuan Y., et al. Effect of smoking on chromosomes compared with that of radiation in the residents of a high-background radiation area in China. J Radiat Res 2004, 45:441-446.
34. Demirhan O., Taştemir D. Cytogenetic effects of ethanol on chronic alcohol users. Alcohol Alcohol 2008, 43(2):127-136.
35. Corbin S., Neilly M.E., Espinosa R., Davis E.M., McKeithan T.W., Le Beau M.M. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res 2002, 62(12):3477-3484.
36. Whang-Peng J., Kao-Shan C.S., Lee E.C., Bunn P.A., Carney D.N., Gazdar A.F., et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 1982, 215:181-182.
37. Hibi K., Takahashi T., Yamakawa K., Ueda R., Sekido Y., Ariyoshi Y., et al. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 1992, 7:445-449.
38. Dammann R., Takahashi T., Pfeifer G.P. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001, 20:3563-3567.
39. Mikami Y., Hisatsune A., Tashiro T., Isohama Y., Katsuki H. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem Biophys Res Commun 2009, 379(4):1060-1065.
40. Kuemmel A., Single K., Bittinger F., Faldum A., Schmidt L.H., Sebastian M., et al. TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer 2009, 63(1):98-105.
41. Yanada M., Yaoi T., Shimada J., Sakakura C., Nishimura M., Ito K., et al. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 2005, 14(4):817-822.